Phathom Pharmaceuticals, Inc. Consolidated Net Income/Loss

Consolidated Net Income/Loss of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Consolidated Net Income/Loss growth rates and interactive chart.


Highlights and Quick Summary

  • Consolidated Net Income/Loss for the quarter ending September 29, 2021 was $-36.7 Million (a 0.3% increase compared to previous quarter)
  • Year-over-year quarterly Consolidated Net Income/Loss decreased by -31.75%
  • Annual Consolidated Net Income/Loss for 2020 was $-129 Million (a -49.41% decrease from previous year)
  • Annual Consolidated Net Income/Loss for 2019 was $-255 Million (a 19708.31% increase from previous year)
  • Twelve month Consolidated Net Income/Loss ending September 29, 2021 was $-162 Million (a 1.61% increase compared to previous quarter)
  • Twelve month trailing Consolidated Net Income/Loss increased by 25.34% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$-162 Million $-159 Million $-144 Million $-129 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Consolidated Net Income/Loss of Phathom Pharmaceuticals, Inc.

Most recent Consolidated Net Income/Lossof PHAT including historical data for past 10 years.

Interactive Chart of Consolidated Net Income/Loss of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-36.66 $-36.55 $-34.84
2020 $-53.72 $-34.11 $-21.1 $-20.14 $-129.07
2019 $-98.01 $-68.11 $-87.76 $-1.25 $-255.13
2018 $-0.29 $-1.29

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.